Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 275

Results For "Development"

2906 News Found

Agilent Technologies Foundation partners with five hospitals for Covid-19 research
Digitisation | August 19, 2021

Agilent Technologies Foundation partners with five hospitals for Covid-19 research

Agilent Technologies Inc. announced the contribution of Agilent AriaMx Real-Time qPCR instruments to five research hospitals in India to support their COVID-19 initiatives and help them serve the community at large


Semglee approval to provide huge opportunities in the US insulin biosimilar market
Biotech | August 19, 2021

Semglee approval to provide huge opportunities in the US insulin biosimilar market

FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.


Sai Life Sciences opens discovery biology facility in Hyderabad
Drug Approval | August 19, 2021

Sai Life Sciences opens discovery biology facility in Hyderabad

The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others


Finding a cure for HIV
Drug Approval | August 19, 2021

Finding a cure for HIV

The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.


EpiEndo Pharma secures  EUR 20 Million Series A funding for Macrolide
Biotech | August 18, 2021

EpiEndo Pharma secures EUR 20 Million Series A funding for Macrolide

The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication


Novartis announces positive results from Phase 3 trials of Beovu for diabetes
Drug Approval | August 18, 2021

Novartis announces positive results from Phase 3 trials of Beovu for diabetes

Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one


Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %
Biotech | August 18, 2021

Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik


Suven Life Sciences announces Phase 3 clinical trial of Masupirdine
Biotech | August 17, 2021

Suven Life Sciences announces Phase 3 clinical trial of Masupirdine

This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024


Lupin receives tentative U.S. FDA approval for Brivaracetam tablets
Drug Approval | August 17, 2021

Lupin receives tentative U.S. FDA approval for Brivaracetam tablets

Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older


Antiviral face mask capable of inactivating COVID19
News | August 16, 2021

Antiviral face mask capable of inactivating COVID19

The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)